Xvivo Perfusion AB (publ) (XVIVO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you so much. Good morning and good afternoon everyone and welcome to Exvivo's earning call for the first quarter of 2026. We can go to slide number two and just today's presenter are me, Kristoffer Rosenblatt, calling in from the 2026 ISHCT conference in Toronto, Canada, and Kristoffer Nordström, CFO, calling in from Philadelphia in the United States. And with that, we can go to slide number three, financial at the glance. So we see that the first quarter of this year showed a 23% organic top line growth. This is equivalent to an 18% organic top line growth if we adjust for the US cap trial revenue compared to the same quarter last year. EBITDA was kept at the healthy level resulting in a positive cashflow for the second consecutive quarter. The CFO, Christopher Nordström, will get more into the details on sales, cross-margin and EBITDA later in this presentation. Short on the segments, both the thoracic and abdominal segments are growing rapidly in both regions, which are North America and Europe. The long market trend we saw in Q4 last year continue into 2026 with a good long market with good underlying growth. And we see that a larger sales footprint supporting more customers is paying off. I'm also very pleased with the strong kidney sales in the quarter, partly fueled by the Canadian launch and a growing interest in the United States. We will come back later in this presentation on the progress for the service segment, the actions we have taken and how we will execute to become the preferred partner to all the Transplan teams. And with that we can go over to the highlights of the quarter and you can actually jump straight to slide number five where we see that the highlight very very busy quarter we took many important steps last year and this quarter and ...